Dicerna, Novo Nordisk pen multi-target agreement for cardio-metabolic therapies
Dicerna Pharmaceuticals Inc. and Novo Nordisk AS are teaming up to discover and develop therapies for liver-related cardio-metabolic diseases.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.